» Articles » PMID: 6311839

Plasminogen Activators of the Pituitary Gland: Enzyme Characterization and Hormonal Modulation

Overview
Journal J Cell Biol
Specialty Cell Biology
Date 1983 Oct 1
PMID 6311839
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

We studied plasminogen activator (PA) of the rat pituitary gland in organ and cell monolayer culture. Both anterior and intermediate lobes contain, synthesize and secrete a mixture consisting of the two known types of PA: urokinase and so-called tissue PA. Both enzymes were formed essentially by all PA secreting cells, and PA was identified specifically in mammotrophs, corticotrophs, and luteinizing hormone containing gonadotrophs. Pituitary PA production was modulated on exposure to a variety of biological effectors: anterior lobe PA secretion was stimulated by agents that raised intracellular cAMP concentration; his process depended on de novo enzyme synthesis. Enzyme production was repressed by androgens and glucocorticoids. When anterior lobe cultures were maintained in plasminogen-free media, the extracellular, secreted forms of ACTH consisted almost exclusively of the high molecular weight forms (31,000 and 23,000); the smaller forms (13,000 and 4,500) were also found in the extracellular medium of cultures supplemented with plasminogen. In contrast, the size distribution of intracellular ACTH species was unaffected by the presence of plasminogen. These results resemble those previously obtained with pancreatic islets and are consistent with the possibility that plasmin, generated by PA secretion, participates in prohormone processing. PA synthesis in intermediate lobe explants was stimulated by exposure to dibutyryl cAMP, and repressed by hydrocortisone. In accordance with the dopaminergic control of intermediate lobe function in some vertebrates, apomorphine strongly repressed PA synthesis in intermediate, but not anterior lobe cultures.

Citing Articles

Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells.

Hill R, Parmar P, Coates L, Mezey E, Pearson J, Birch N Biochem J. 2000; 345 Pt 3:595-601.

PMID: 10642518 PMC: 1220794.


Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland.

Kristensen P, Nielsen L, Andresen P, Larsson L, Dano K J Cell Biol. 1985; 101(1):305-11.

PMID: 3891762 PMC: 2113636. DOI: 10.1083/jcb.101.1.305.


Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.

OSSOWSKI L, Belin D Mol Cell Biol. 1985; 5(12):3552-9.

PMID: 3837848 PMC: 369186. DOI: 10.1128/mcb.5.12.3552-3559.1985.


Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues.

Christensen L, Johansen N, Jensen B, Clemmensen I Histochemistry. 1987; 87(3):195-9.

PMID: 3308790 DOI: 10.1007/BF00492409.


Tissue-type plasminogen activator in rat adrenal medulla.

Kristensen P, Hougaard D, Nielsen L, Dano K Histochemistry. 1986; 85(5):431-6.

PMID: 3096916 DOI: 10.1007/BF00982674.


References
1.
Wilson E, Reich E . Plasminogen activator in chick fibroblasts: induction of synthesis by retinoic acid; synergism with viral transformation and phorbol ester. Cell. 1978; 15(2):385-92. DOI: 10.1016/0092-8674(78)90007-7. View

2.
Hudson P, Haley J, Cronk M, Shine J, NIALL H . Molecular cloning and characterization of cDNA sequences coding for rat relaxin. Nature. 1981; 291(5811):127-31. DOI: 10.1038/291127a0. View

3.
Strickland S, Mahdavi V . The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell. 1978; 15(2):393-403. DOI: 10.1016/0092-8674(78)90008-9. View

4.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

5.
Sando H, Borg J, Steiner D . Studies on the secretion of newly synthesized proinsulin and insulin from isolated rat islets of Langerhans. J Clin Invest. 1972; 51(6):1476-85. PMC: 292285. DOI: 10.1172/JCI106944. View